Pathogenesis and novel treatment options for non-alcoholic steatohepatitis (Q38731060)

5 September 2017

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis (English)

1 reference

5 September 2017

0 references

2

1 reference

5 September 2017

3

Grace Lai-Hung Wong

1 reference

5 September 2017

5

Henry Lik-Yuen Chan

1 reference

5 September 2017

1

Vincent Wai-Sun Wong

1 reference

5 September 2017

6

Geoffrey C Farrell

1 reference

5 September 2017

Jun Yu

4

1 reference

5 September 2017

10 August 2016

1 reference

The lancet. Gastroenterology & hepatology

5 September 2017

1 reference

5 September 2017

1

1 reference

5 September 2017

1

1 reference

5 September 2017

56-67

1 reference

Nonalcoholic fatty liver disease

5 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Extrahepatic complications of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Should we lower lipids in nonalcoholic fatty liver disease?

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Pathophysiological mechanisms and therapeutic potentials of macrophages in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

1 reference

7 January 2021

Inflammasome is a central player in the induction of obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Obesity, insulin resistance, NASH and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Lipid-induced insulin resistance is associated with increased monocyte expression of scavenger receptor CD36 and internalization of oxidized LDL.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Autophagy and regulation of lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Autophagy in immunity and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Autophagy in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Association between bariatric surgery and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Effect of vildagliptin on hepatic steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Statins and non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Statin use and non-alcoholic steatohepatitis in at risk individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

A lipidomic analysis of nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Bile acid receptors and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Transcriptional regulation of autophagy by an FXR-CREB axis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

FXR is a molecular target for the effects of vertical sleeve gastrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Microbiome in NAFLD and ALD

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Human lysyl oxidase-like 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Non-alcoholic fatty liver disease: is iron relevant?

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Red wine coming up roses for intestinal ischemia reperfusion injury: role for resveratrol?

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2816%2930011-5

7 January 2021

10.1016/S2468-1253(16)30011-5

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

28404113